Thomas Foster, MD
Neurology · Mobile, ALNPI 1992962856
Payments from drug & device makers
Across 442 payments — averaging $115.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$48K
- Biogen$345
- Novartis$317
- Teva Pharmaceuticals USA, Inc.$278
- Amgen$253
- UCB, Inc.$215
- plus $2K from 30 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 245 | $48,149 |
| Biogen | 18 | $345 |
| Novartis | 25 | $317 |
| Teva Pharmaceuticals USA, Inc. | 16 | $278 |
| Amgen(2 entities) | 15 | $253 |
| UCB, Inc. | 12 | $215 |
| Impel Pharmaceuticals Inc. | 16 | $207 |
| AstraZeneca | 8 | $139 |
| Arbor Pharmaceuticals, Inc. | 11 | $127 |
| EMD Serono, Inc. | 7 | $107 |
| Lundbeck LLC | 4 | $101 |
| Lilly USA, LLC | 5 | $77 |
| Sunovion Pharmaceuticals Inc. | 6 | $77 |
| Acadia Pharmaceuticals Inc | 6 | $73 |
| Neurocrine Biosciences, Inc. | 4 | $69 |
| Ipsen Biopharmaceuticals, Inc | 4 | $61 |
| Amneal Pharmaceuticals LLC | 5 | $57 |
| Bristol Myers Squibb | 4 | $53 |
| Genentech USA, Inc. | 4 | $52 |
| Medtronic | 3 | $42 |
| Pfizer | 2 | $40 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| MDD US Operations, LLC | 1 | $37 |
| Avion Pharmaceuticals | 2 | $35 |
| Sanofi | 2 | $35 |
| Johnson & Johnson | 2 | $31 |
| Adamas Pharmaceuticals, Inc. | 2 | $27 |
| Upsher-smith Laboratories LLC | 2 | $25 |
| Supernus Pharmaceuticals, Inc. | 2 | $24 |
| Merz Pharmaceuticals, LLC | 1 | $22 |
| Eisai Inc. | 1 | $17 |
| Tanabe Pharma America, Inc. | 1 | $16 |
| Averitas Pharma Inc. | 1 | $14 |
| Catalyst Pharmaceuticals, Inc. | 1 | $14 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
How this compares
$51,203 in reported general payments places this provider in the 80th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Mobile
- Daniel DeesMobile$894K
- Hayden LongMobile$386K
- William KilgoMobile$334K
- John HintonMobile$270K
- Charles MarkleMobile$212K
- Bassam BassamMobile$197K
- Dean NaritokuMobile$164K
- Matthew McLeanMobile$113K
- Laura MintoMobile$92K
- Steve CordinaMobile$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.